No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
Eiken Chemical Co., Ltd. is a Japanese manufacturer and distributor specializing in clinical diagnostic products and medical equipment. The company excels in developing diagnostic solutions for diverse medical fields, encompassing biochemical analysis, immunology, serology, dry chemical assays, and automated diagnostic systems. A significant offering is the OC-SENSOR, an automated immunochemical fecal test designed to identify gastrointestinal bleeding linked to conditions such as colorectal cancer, polyps, and diverticulitis. Its comprehensive product portfolio further includes real-time turbidimeters, temperature-controlled equipment, various amplification and fluorescence detection reagents for research applications, and general detection kits. Eiken Chemical also produces a variety of microbiology-related products, alongside additional immunological and serological reagents. Established in Tokyo, Japan, in 1939, the company initially operated as Nihon Eiyokagaku Co., Ltd. until its rebranding to Eiken Chemical Co., Ltd. in 1969.
www.eiken.co.jpNo one on the platform currently holds 4549.T.
No tracked institution reports a position in 4549.T as of their last filing.
No one on the platform has traded 4549.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.5% | 9.6% | 10.6% | — | — | — |
| Rev. Growth % | 3.4% | 1.6% | ||||
| Profit Margin % | 8.8% | 9.7% | 9.7% | |||
| Free Cash Flow Margin % | -4.1% | 3.8% | 5.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $43.6B | +3.2% | $91.90 | $91.90–$91.90 | — | 1 |
| 2028 | $46.0B | +5.5% | $107.50 | $107.50–$107.50 | — | 1 |
| 2029 | $48.2B | +4.9% | $118.10 | $118.10–$118.10 | — | 1 |
| 2030 | $50.5B | +4.8% | $128.60 | $128.60–$128.60 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| -0.58% |
| $63.0B |
| — |
| 4559.TZeria Pharmaceutical Co., Ltd. | $2014.00 | -0.10% | $88.8B | — |
| 4565.TNxera Pharma Co., Ltd. | $1233.00 | +0.90% | $113.1B | — |
Source: Financial Modeling Prep · peers by sector/industry